Core Insights - The latest shareholder equity disclosures were made by CLASSIFIED GP, Prosperity REIT, Stone Four Pharmaceutical Group, Da Chang Group, and Wang Chen Technology Holdings on October 13, 2025 [1] Group 1: Shareholding Changes - VMS Investment completely divested from CLASSIFIED GP, reducing its holdings from 3.4 million shares to 0 shares, resulting in a holding percentage of 0% [2] - ESR Asset increased its stake in Prosperity REIT from 71.5981 million shares to 76.0546 million shares, raising its holding percentage to 3.70% [2] - Qu Jiguang slightly increased his holdings in Stone Four Pharmaceutical Group from 1.211 billion shares to 1.213 billion shares, maintaining a holding percentage of 41.08% [2] - Chen Bin's holdings in Da Chang Group remained unchanged at 277 million shares, with a holding percentage of 44.92% [2] - Beijing Zhuiyuan Wealth Capital reduced its holdings in Wang Chen Technology Holdings from 8.0364 million shares to 6.0273 million shares, resulting in a holding percentage of 4.22% [2] - Liu Chengmin's holdings in Wang Chen Technology Holdings decreased from 10.1794 million shares to 7.0988 million shares, with a holding percentage of 4.97% [2]

香港联交所最新数据显示，10月9日，China Pharmaceutical Company Limited增持石四药集团(02005)123 万股，每股作价2.96港元，总金额约为364.08万港元。增持后最新持股数目约为8.86304亿股，持股比例 为30.03%。 ...

智通财经APP获悉，香港联交所最新数据显示，10月9日，China Pharmaceutical Company Limited增持石 四药集团(02005)123万股，每股作价2.96港元，总金额约为364.08万港元。增持后最新持股数目约为 8.86304亿股，持股比例为30.03%。 ...

Core Points - The company, Shijiazhuang Pharmaceutical Group, announced a share buyback on October 10, purchasing 1.5 million shares at prices ranging from HKD 2.940 to HKD 2.970, totaling HKD 4.4295 million [2] - The stock closed at HKD 2.960 on the same day, reflecting a decrease of 0.67%, with a total trading volume of HKD 26.5166 million [2] - Year-to-date, the company has conducted 14 buybacks, acquiring a total of 40.90 million shares for a cumulative amount of HKD 121 million [2] Buyback Details - The latest buyback on October 10 involved 150,000 shares at a maximum price of HKD 2.970 and a minimum price of HKD 2.940, costing HKD 4.4295 million [2] - Previous buybacks include: - October 8: 200,000 shares at a maximum price of HKD 2.880, totaling HKD 5.7266 million [2] - October 6: 300,000 shares at a maximum price of HKD 2.930, totaling HKD 8.6989 million [2] - September 23: 500,000 shares at a maximum price of HKD 2.960, totaling HKD 14.6748 million [2] - September 12: 90,000 shares at a maximum price of HKD 3.060, totaling HKD 2.7511 million [2] - September 11: 600,000 shares at a maximum price of HKD 3.040, totaling HKD 18.1433 million [2] - June 5: 540,000 shares at a maximum price of HKD 2.800, totaling HKD 15.0958 million [2] - June 4: 345,000 shares at a maximum price of HKD 2.850, totaling HKD 9.7254 million [2] - June 2: 755,000 shares at a maximum price of HKD 2.780, totaling HKD 20.9838 million [2] - April 2: 280,000 shares at a maximum price of HKD 3.440, totaling HKD 9.5882 million [2] - January 16: 50,000 shares at a maximum price of HKD 3.210, totaling HKD 1.6011 million [2] - January 15: 160,000 shares at a maximum price of HKD 3.230, totaling HKD 5.1320 million [2] - January 14: 70,000 shares at a maximum price of HKD 3.250, totaling HKD 2.2593 million [2] - January 2: 50,000 shares at a maximum price of HKD 3.450, totaling HKD 1.7193 million [2]

石四药集团(02005)发布公告，于2025年10月10日该公司斥资442.95万港元回购150万股，回购价格为每 股2.94-2.97港元。 ...

格隆汇10月10日丨石四药集团(02005.HK)公告，10月10日耗资442.95万港元回购150万股，每股回购价 2.94-2.97港元。 ...

智通财经APP讯，石四药集团(02005)发布公告，于2025年10月10日该公司斥资442.95万港元回购150万 股，回购价格为每股2.94-2.97港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年10月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

| 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 (02005) | China Pharmaceutical Company Limited | 好仓 | 8.85 亿股 | 8.86 亿股 | 30.03%(最新) 29.99%(前次) | | 石药集团(01093) | | | | | 24.62%(前次) | | 石四药集团 (02005) | 曲继广 | 好仓 | 12.10 亿股 | 12.11 亿股 | 41.03%(最新) 40.99%(前次) | | | 蔡东晨 | 好仓 | 28.37 亿股 | 28.39 亿股 | 24.64%(最新) | 智通财经APP获悉，石四药集团(02005)、石药集团(01093)于2025年10月10日进行了最新股东权益披 露。 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 ...

Core Insights - The latest shareholder equity disclosures for China Information Technology (08178) and Stone Four Pharmaceutical Group (02005) were conducted on October 9, 2025 [1] Group 1: Shareholding Changes - Huang Jingzhao increased his holdings in China Information Technology from 1.2846 million shares to 1.3777 million shares, representing a holding percentage change from 1.75% to 1.37% [2] - Zhang Rong's holdings in China Information Technology rose from 20.226 million shares to 20.299 million shares, with a decrease in holding percentage from 27.61% to 20.08% [2] - Qu Jiguang's stake in Stone Four Pharmaceutical Group increased slightly from 1.208 billion shares to 1.210 billion shares, with a marginal increase in holding percentage from 40.92% to 40.99% [2]